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clinical strains and transformants had
bands of β-lactamase activity with an
alkaline pI of 7.6 and 5.4. Polymerase
chain reaction (PCR) amplification of
the 26 clinical isolates was positive
for blaCTX-M and blaTEM (7). The 26
strains of E. coli had the same profile
by repetitive-element PCR and
pulsed-field gel electrophoresis, while
unrelated control strains had very dif-
ferent profiles. Sequencing in strains
isolated from four of the patients iden-
tified a CTX-M-15 β-lactamase and a
TEM-1 β-lactamase. The four strains
were related to the phylogenetic
group B2 and produced the iutA (fer-
ric aerobactin receptor), YuA
(Yersinia siderophore receptor), and
fimH (type I fimbriae) virulence fac-
tors (8). Incidence of colonization or
infection by the culprit strain was
34.3% (12 of 35 patients) within the
initial 4-month period and 55.3% (26
of 47 patients) over a 1-year period.
Intensified hygienic procedures
implemented in January 2002 con-
tributed to a decrease in the number of
cases in February only; since then, a
regular increase of new cases extend-
ed the outbreak and caused problems
with controlling it. All urinary tract
infections were successfully treated
with a 15-day course of trimethoprim-
sulfamethoxazole; however, reinfec-
tion occurred in some. Neither incon-
tinence (p = 0.35), dementia (p =
0.22), nor previous antibiotic treat-
ment (amoxicillin, amoxicillin-clavu-
lanic acid, extended-spectrum
cephalosporins, and fluoroquinolones
[p = 1.00, 0.30, 0.12, 0.52, respective-
ly]) appeared to be risk factors for
infection or colonization in our study,
but the number of patients is too small
to reach a conclusion. However,
patients that were infected or colo-
nized had greater functional impair-
ment, especially incontinence and
dementia. Nonambulatory status,
decubitus ulcers, and feeding tubes
were not risk factors for acquiring
ESBL-producing E. coli in our study.
The outbreak has not been con-
trolled: 13 patients have persistent
digestive-tract colonization. Diffi-
culties encountered in controlling
such outbreaks may be explained by
several factors. Patients cannot be
easily isolated in long-term care facil-
ities. Strict isolation and limitation of
activity and mobility cannot always
be applied because of their impact on
social activities.
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Do Antiborrelial
Antibodies Suggest
Lyme Disease in
Cuba? 
To the Editor: Lyme disease is the
most common vector-borne disease in
the United States and parts of Eurasia
(1). It represents a considerable
emerging infectious disease threat
because of its consequences to human
health and the difficulties in prevent-
ing and controlling it (2,3).
In Cuba, Lyme borreliosis has
never been reported. However, in the
last 20 years ixodid ticks, mainly
Amblyomma cajennenses, have been
found in the human population in the
Cuban village of Las Terrazas, Pinar
del Río. These ixodid bites were fre-
quent and widespread, especially in
children, many of whom were hospi-
talized without a confirmatory labora-
tory diagnosis. Affected persons had
symptoms associated with Lyme dis-
ease such as erythematous macules or
papules, fever, fatigue, malaise,
headache, arthralgias, myalgias,
meningitis, peripheral radiculoneu-
ropathies, and myocarditis (4). 
A Cuban researcher, a specialist in
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ixodid ticks, was bitten several times
by the ticks; dermatologic and neuro-
logic symptoms compatible with
Lyme disease (skin lesions, hyperes-
thesia with loss of reflexes, loss of
muscular coordination, and fecal
incontinence) developed. Borreliosis
was not diagnosed at this stage; the
diagnosis was either myeloradiculitis
or Guillain-Barré syndrome. Three
years later, a serologic diagnosis of
Lyme disease was made by indirect
immunofluorescence in a laboratory
in the Czech Republic (5). 
During 1998, serum samples from
14 persons who lived in the village
Las Terrazas and had epidemiologic
and clinical evidence of Lyme dis-
ease, were studied in our laboratory.
We used an immunoglobulin (Ig) G
and IgM–enzyme-linked immunoab-
sorbent assay (ELISA) kit (Enzygnost
Borreliosis, Behring, Marburg,
Germany), in which each strip con-
tained wells coated with inactivated
borrelial antigen (detergent extract
from strain isolate PKo [Borrelia
afzelii]), to detect specific antibodies
to B. burgdorferi complex. The assays
were performed according to the man-
ufacturer’s instructions. In our study,
five serum samples had positive IgM
titers and one near the cutoff value by
IgM and IgG. 
ELISA has been widely used to
detect antibodies to B. burgdorferi;
however, this assay is not standard-
ized, which results in different levels
of sensitivity and specificity. False-
positive results may occur, especially
when serum samples are obtained
from persons with other illnesses (6).
To study possible cross-reactions
with other infectious illnesses, differ-
ent serologic tests were applied to the
positive serum samples by using
ELISA. One sample was weakly reac-
tive to human leptospirosis (indirect
hemagglutination assay with erythro-
cyte-sensitive substance antigen
[Labiofam, Havana, Cuba]), but no
samples were reactive to syphilis
(rapid plasma reagin [Imefa, Havana,
Cuba] and hemagglutination of
Treponema pallidum [Oxoid,
Diagnostic Reagents, Basingstoke,
UK]). No indication of other infec-
tious diseases was found.
All serum samples positive by
ELISAwere also analyzed by IgG and
IgM Western blotting in the spirochete
laboratory at the University of Trieste,
Italy. The Western blotting was per-
formed with a protein profile from
whole–cell strain PKo and by applying
the criteria of positivity described by
Hauser et al. (7). Two serum samples
showed clear IgM antibody bands to
41- and 23-kDa proteins. No IgG
bands were observed. This test report-
edly is more sensitive than ELISA for
IgM detection (6).
We investigated the clinical mani-
festations of the patients with positive
Western blotting. We found that one
of the patients had been bitten sever-
al times by ticks and had an erythe-
matous rash around the different bite
sites; the rashes reddened and
expanded over the course of a few
days, with partial central clearing.
The patient also had fever,
hepatosplenomegaly, adenopathies,
joint pain, and some nonspecific
symptoms. He was given erythromy-
cin before the laboratory results were
confirmed and had a satisfactory
recovery. In similar situations, repeat
testing would be highly advisable.
This was the same patient with low
levels of antibodies to Leptospira.
Investigating the symptoms of the
other patient was not possible.
The presence of IgM antibodies is
frequently confirmed in the early
stage of Lyme disease (6). The
patient’s history of being bitten by an
A. cajennenses tick, clinical manifes-
tations of Lyme borreliosis, and spe-
cific antibodies to B. burgdorferi
complex suggest the diagnosis of
Lyme disease.
A. cajennenses has not been
reported as a vector for Lyme disease.
However, it is very abundant and
aggressive in Cuba, and bites from
this species are common. The genus
Ixodes, the main vector of B. burgdor-
feri sensu lato, has not been reported
in the area of the study. Several arti-
cles describe a new species in the
United States, B. lonestari. B. lone-
stari in A. americanum has been con-
firmed in humans with erythema
migrans (8,9). 
No serologic test is available for
antibodies to B. lonestari. That we
found antiborrelial-complex antibod-
ies may suggest the presence of a new
species in this antigenic complex con-
taining cross-reactive antigens, but
many other studies are necessary to
confirm it. This study represents the
first serologic report of antiborrelial
antibodies in Cuba. It suggests that
Lyme borreliosis is present and that
new cases can be expected in our
country. Further laboratory studies are
necessary for a more accurate diagno-
sis of this emerging infectious disease
in Cuba.
Islay Rodríguez,* 
Carmen Fernández,* 
Marina Cinco,† 
Rodobaldo Pedroso,‡ 
and Omar Fuentes*
*Institute of Tropical Medicine Pedro Kourí,
Havana, Cuba; †University of Trieste,
Trieste, Italy; and ‡Medical Assistance
Center of Las Terrazas Village, Cuba
References
1. Wormser GP. Vaccination as a modality to
prevent Lyme disease. A status report.
Infect Dis Clin North Am. 1999;13:135–48.
2.  Anderson JF. Preventing Lyme disease.
Rheum Dis Clin North Am.
1989;15:757–66.
3. Malouin R, Winch P, Leontsini E, Glass G,
Simon D, Hayes EB, et al. Longitudinal
evaluation of an educational intervention
for preventing tick bites in an area with
endemic Lyme disease in Baltimore
County, Maryland. Am J Epidemiol.
2003;157:1039–51.
4.  Grandío O, Fernández A, Fernández M,
Valera R, Fuentes O, Pelegrino J. Informe
preliminar sobre investigaciones realizadas
en el poblado “Las Terrazas”, Sierra del
Rosario, sobre la existencia de la
Enfermedad de Lyme. Rev Cubana
Pediatría. 1988;60:773.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 9, September 2004 1699LETTERS
5.  Rodríguez I, Pedroso R, Fernández C,
Cinco M, Fuentes O. ¿Enfermedad de
Lyme en Cuba? Presentación de posibles
casos. Rev Cubana Med Trop.
2003;55:41–3.
6.  Engstrom SM, Shoop E, Johnson RC.
Immunoblot interpretation criteria for sero-
diagnosis of early Lyme disease. J Clin
Microbiol. 1995;33:419–27.
7. Hauser U, Lehnert G, Wilske B. Validity of
interpretation criteria for standardized
Western blots (immunoblots) for serodiag-
nosis of Lyme borreliosis based on sera col-
lected throughout Europe. J Clin Microbiol.
1999;37:2241–7.
8.  James AM, Liveris D, Wormser GP,
Schwartz I, Montecalvo MA, Johnson BJ.
Borrelia lonestari infection after a bite by
an Amblyomma americanum tick. J Infect
Dis. 2001;183:1810–4.
9. Stromdahl EY, Williamson PC, Kollars TM,
Evans SR, Barry RK, Vince MA, et al.
Evidence of Borrelia lonestari DNA in
Amblyomma americanum (Acari:
Ixodiadae) removed from humans. J Clin
Microbiol. 2003;41:5557–62
Address for correspondence: Islay Rodriquez,
Laboratory of Spirochetes, Institute of Tropical
Medicine “Pedro Kourí,” PO Box 601,
Marianao 13, Havana City, Cuba; fax: 53-7-
204-6051; email: islay@ipk.sld.cu 
Human 
Herpesvirus 6
Encephalomyelitis
To the Editor: Denes et al. (1)
reports successful treatment of human
herpesvirus 6 (HHV-6) encephalo-
myelitis. The patient was an immuno-
competent young woman whose
symptoms were fever, urinary reten-
tion, blurred vision, quadriparesis,
bilateral papillitis, and optic neuritis.
Magnetic resonance imaging (MRI)
showed multiple lesions on the spinal
cord white matter and the left thala-
mus, and the cerebral spinal fluid
(CSF) showed inflammation. The
patient was treated with acyclovir for
3 days, high-dose methylprednisolone
for 5 days, cidofovir for 1 day, and
ganciclovir for 15 days, starting on
day 23 of hospitalization. By estab-
lishing a relationship between antivi-
ral drug doses, serial determinations
of HHV-6 DNA by polymerase chain
reaction (PCR) in CSF, and neurolog-
ic improvement, Denes et al. conclud-
ed that antiherpesvirus drugs led to
her recovery. 
This case fits well in the spectrum
of acute disseminated encephalo-
myelitis (ADEM), an inflammatory
demyelinating disease of the central
nervous systems of children and
young adults, which occur in close
temporal relationship with several
infectious illnesses and immunizations
(2–6). The disease has particular
predilection to the optic nerves, spinal
cord, brainstem, basal ganglia, and
cerebral and cerebellar hemispheres.
Maximal neurologic deficits are
reached within several days, and reso-
lution takes weeks or months. The
condition is typically monophasic, but
relapses have been reported (7).
Histologic multifocal areas of inflam-
mation and demyelinization are found.
In the pathogenesis of ADEM, an ini-
tial injury caused by an infectious
agent, followed by a secondary
autoimmune response, has been postu-
lated, and animal models have provid-
ed experimental support; both CD4
and CD8 T cells have been implicated
in a secondary autoimmune response
(6). Despite the lack of controlled
studies, corticosteroids are widely
used to treat ADEM and high-dose
methylprednisolone is the drug of
choice (3,4). The largest series of
ADEM in adults included 40 patients
with a mean follow-up period of 38
months. The patients were given a
standardized treatment regimen of
methylprednisolone, 500 mg daily
intravenously for 5 days, with no addi-
tional therapy if they recovered com-
pletely. In patients with persistent neu-
rologic deficits, the initial intravenous
therapy was followed by a regimen of
oral methylprednisolone, which was
slowly tapered over 4 to 6 weeks. In
patients with no response to this thera-
py, or whose condition had deteriorat-
ed during therapy, cyclophosphamide
was given to seven patients, and
immunoglobulin was given to one
patient. Thirty-eight of 40 patients
improved during the acute phase of the
illness; in 7, symptoms completely
resolved. One patient’s condition
remained unchanged and one patient
died; no antiviral drugs were given (5).
The neurotropism of HHV-6 and
that the CNS may be a site of viral
persistence or latency are well recog-
nized (8,9). On autopsy, evidence of
fulminant encephalitis with HHV-6
DNAdemonstrated by PCR, immuno-
histochemical staining, or nucleic acid
hybridization, confirms that HHV-6
causes acute CNS disease (8).
Nevertheless, whether evidence of
HHV-6 DNAin CSF demonstrated by
PCR can be solely relied on is debat-
able. HHV-6 DNAwas detected in the
CSF of 41 (28.9%) of 142 children
with a history of HHV-6 infection (9).
HHV6-DNA was detected in the CSF
of 47 (61%) of 77 children examined
after primary HHV-6 infection. In the
remaining 30 children (39%), HHV-6
DNA was detected in both peripheral
blood mononuclear cells and CSF
samples. HHV-6 variant Awas detect-
ed more frequently in CSF than in
specimens of other sites, which sug-
gests that HHV-6A has greater neu-
rotropism (10). 
The role of HHV-6 in acute multi-
focal neurologic disease in immuno-
competent adults requires additional
observation, and its role in multiple
sclerosis is in question. Much can be
learned from careful study of patients
(1).   
I caution the casual reader who
may conclude that using antiviral
drugs against herpes viruses is recom-
mended when acute mutlifocal neuro-
logic disease clinically compatible
with ADEM is indicated. High-dose
IV methylprednisolone is the most
utilized treatment, and the patient in
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